Life Science Pharmaceuticals signs licensing agreement with Abbott
The agreement provides Abbott with exclusive worldwide rights to Antibody 806, which targets the clinically validated pathway involving the epidermal growth factor receptor (EGFr). Antibody 806 is differentiated
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.